Truly a Banner Season for SWOG

Saying that SWOG has had a highly productive summer would be something of an understatement. In fact, the group has activated nine clinical trials since June!

Five are hematology trials, including one myeloMATCH sub-study and a SWOG CTP trial. Breast, lung, and cancer care delivery are also represented, as is rare cancers in the form of a sarcoma trial. Here are the nine, in order of activation.

S2424CD
S2424CD is testing an intervention (known as A-PACT) designed to improve goals-of-care communication between providers and patients with advanced cancer. This NCORP-only study will assess the intervention’s impact on patient hospitalization rates and on measures of patient anxiety and depression. 

S2504 PIRAMID
S2504 PIRAMID is the first randomized trial in the US for patients with Richter transformation – the progression of CLL (or of small lymphocytic lymphoma) into aggressive lymphoma. The study is evaluating the addition of pirtobrutinib to standard R-CHOP treatment. S2504 was highlighted at the spring group meeting in a joint pre-launch kickoff session with study S2506. A recording is available to SWOG members (login required).

26CTP.LEUK02 APEX-MF
SWOG Clinical Trials Partnerships activated its third trial early this summer – 26CTP.LEUK02, or APEX-MF. Conducted with no federal funding, this randomized trial compares momelotinib to dose-adjusted ruxolitinib for patients with treatment-naïve cytopenic myelofibrosis. SWOG member sites interested in learning more should visit the LEUK02 APEX-MF page. 

S2505
S2505 is a de-escalation study testing whether short-course radiation therapy is non-inferior to standard RT in patients with resectable soft-tissue sarcoma. Learn more about the trial at an S2505 kickoff session at the fall group meeting in Chicago.

MM1OA-S04 (myeloMATCH)
MM1OA-S04 is also a de-escalation study, enrolling patients newly diagnosed with acute myeloid leukemia who are 60 years or older and are not candidates for intensive therapy. The study asks if short-duration venetoclax (14 days per cycle) is non-inferior to standard-duration venetoclax (28 days per cycle), both given in combination with the drug ASTX727.

S1900N (Lung-MAP)
S1900N is for patients with advanced non-small cell lung cancer that has an actionable genomic alteration and which has progressed on a targeted therapy plus chemo. The Lung-MAP portfolio is expanding to include more sub-studies of this sort – testing new treatment options for patients whose NSCLC has progressed on targeted therapy (S1900G, currently enrolling, is another such sub-study).  

S2506 MOZART
S2506 MOZART is enrolling patients with relapsed or refractory marginal zone lymphoma. It’s a three-arm phase 2 study comparing mosunetuzumab alone and in combination with zanubrutinib or polatuzumab vedotin. The study team hopes to identify a winning combination to advance to a phase 3 study. 

S2511
Yet another study that could only be done within the cooperative group system, S2511 is enrolling patients with de novo oligometastatic HER2-positive breast cancer. Those who respond to initial therapy are randomized to standard systemic therapy alone or systemic therapy plus surgery and radiation. The trial asks if a multimodality approach to treating these patients will improve survival (and perhaps even cure a subset of patients).

S2507
SWOG’s newest trial, activated earlier this week, is S2507. This randomized phase 2 adds revumenib to blinatumomab in patients with acute lymphoblastic leukemia or acute leukemia with ambiguous lineage that has a KMT2A translocation. Conducted in collaboration with the Children’s Oncology Group, the trial will enroll adults plus pediatric and adolescent patients from 1 year through 18 years of age. S2507 includes a separate cohort for patients age 55 years or older that tests revumenib in combination with reduced-intensity chemotherapy. 

Nine trials launched over four months is an impressive feat, and all SWOG members and staff who had a hand in this accomplishment should be proud!

We want to give a particular shout-out to our amazing protocol department. Over a four-week stretch this summer, they sandwiched in a volume of major study activities that would normally play out over about six months.

To them we say thank you for all you do for SWOG and our patients.

And to SWOG members we say thank you for opening and enrolling to this abundance of important new studies!